3SBio 
Welcome,         Profile    Billing    Logout  
 24 Products   12 Diseases  24 Products   75 Trials   617 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Retuxira (rituximab biosimilar) / 3SBio
No trials found
Yisaipu (etanercept biosimilar) / Cipla, 3SBio, Abbott
No trials found
darbepoetin alfa (NuPIAO) / 3SBio
No trials found
EPIAO (recombinant human erythropoietin biosimilar) / 3SBio
No trials found
Lei Ning (abatacept biosimilar) / 3SBio
No trials found
Xenopax (daclizumab biosimilar) / 3SBio
No trials found
TRPH 011 / Triphase Accelerator Corporation
No trials found
Aybintio (bevacizumab biosimilar) / Samsung, Mundipharma
No trials found
Cipterbin (inetetamab) / 3SBio
No trials found
nofazinlimab (CS1003) / CStone Pharma
No trials found
ALT-P7 / Alteogen
No trials found
CPGJ-602 / 3SBio
No trials found
CMAB007 (omalizumab biosimilar) / Mabpharm Limited
No trials found
601A / 3SBio
No trials found
pegerythropoietin injection (RD01) / 3SBio
No trials found
SSS17 / 3SBio
No trials found
DJ5 / Shanghai Inst. of Materia Medica, 3SBio
No trials found
608 / 3SBio
No trials found
pegylated irinotecan (SSS22) / 3SBio
No trials found
Remitch OD (nalfurafine hydrochloride orally disintegrating tablet) / Toray, Japan Tobacco, Sumitomo Pharma
No trials found
SSGJ-610 / 3SBio
No trials found
611 / 3SBio
No trials found
CMAB807 (denosumab biosimilar) / 3SBio
No trials found
VTX-0811 / Verseau Therap
No trials found
SSGJ-612 / 3SBio
No trials found
CMAB818 (ranibizumab biosimilar) / 3SBio
No trials found
SSGJ-705 / 3SBio
No trials found
SSGJ-613 / 3SBio
No trials found
VTX-1218 / Verseau Therap
No trials found
TPIAO (recombinant human thrombopoietin) / 3SBio
No trials found
609A / 3SBio
No trials found
NM28-2746 / Numab
No trials found
SSGJ-622 / 3SBio
No trials found
SSGJ-706 / 3SBio
No trials found
SSGJ-619 / 3SBio
No trials found
Intefen (interferon alpha-2a biosimilar) / Biolotus Biotech, 3SBio
No trials found
19H6-Hu / 3SBio
No trials found

Download Options